Article

STAAR gets CE mark for preloaded aspheric silicone IOL

STAAR Surgical Co. received CE mark approval for its KS-3Ai preloaded IOL injection system with an aspheric optic design. The company will now be allowed to market this IOL for use in cataract surgery in 21 countries. STAAR will begin shipments to distributors this month.

STAAR Surgical Co. received CE mark approval for its KS-3Ai preloaded IOL injection system with an aspheric optic design. The company will now be allowed to market this IOL for use in cataract surgery in 21 countries. STAAR will begin shipments to distributors this month.

"Our preloaded silicone IOL has grown significantly in international markets, and, as of first quarter 2006, represented 18% of STAAR's total IOL sales," said David Bailey, president and chief executive officer. "We have seen very strong interest from both doctors and distributors in our new aspheric model."

The company expected to launch the lens into international markets this past May. The IOL is not yet approved for use in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
© 2025 MJH Life Sciences

All rights reserved.